Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax
Date
Authors
Hodder, Anthony N.
Christensen, Janni
Scally, Stephen
Triglia, Tony
Ngo, Anna
Birkinshaw, Richard W.
Bailey, Brodie
Favuzza, Paola
Dietrich, Melanie H.
Tham, Wai Hong
Journal Title
Journal ISSN
Volume Title
Publisher
Access Statement
Abstract
Plasmepsins IX (PMIX) and X (PMX) are essential aspartyl proteases for Plasmodium spp. egress, invasion, and development. WM4 and WM382 inhibit PMIX and PMX in Plasmodium falciparum and P. vivax. WM4 inhibits PMX, while WM382 is a dual inhibitor of PMIX and PMX. To understand their function, we identified protein substrates. Enzyme kinetic and structural analyses identified interactions responsible for drug specificity. PMIX and PMX have similar substrate specificity; however, there are distinct differences for peptide and protein substrates. Differences in WM4 and WM382 binding for PMIX and PMX map to variations in the S' region and engagement of the active site S3 pocket. Structures of PMX reveal interactions and mechanistic detail of drug binding important for development of clinical candidates against these targets.
Description
Citation
Collections
Source
Structure
Type
Book Title
Entity type
Publication